No profile data available.
Almirall, S.a. (ALMRY) is a healthcare company in the skin treatment pharmaceuticals industry, based in Barcelona, Spain, with about 2,097 full-time employees.
It reported revenue of 985.72 million EUR for fiscal year 2024, up 10.2% from fiscal year 2023, and net income of 10.15 million EUR. In Q3 2025 (the quarter ended September 30, 2025) revenue was 260.24 million EUR, up 13.0% from a year before. Its largest business segment, Commercial Areas - Own Network, brought in 86% of segment revenue in fiscal year 2025; Spain was the largest region with 30%. Its market capitalization was $2.98 billion as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.
Almirall reported 985.72 million EUR in revenue for fiscal year 2024, up 10.2% from 894.52 million EUR in fiscal year 2023. In Q3 2025 revenue was 260.24 million EUR.
Commercial Areas - Own Network, with 955.30 million EUR or 86% of segment revenue in fiscal year 2025. Next: Commercial Areas - Licensees (10%) and Other Areas - Corporate Services and Manufacturing (4%).
Spain: 30% of revenue by region in fiscal year 2025, followed by Germany (29%).
$2.98 billion as of October 8, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Kymera Therapeutics, Inc. (KYMR), Oruka Therapeutics, Inc. (ORKA), Arcutis Biotherapeutics, Inc. (ARQT), Trevi Therapeutics, Inc. (TRVI).